Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1157-1165

  Malamou Mitsi, Vassiliki ^a   Crikoni, Olga ^a   Timotheadou, Eleni ^b   Aravantinos, Gerassimos ^c   Vrettou, Eleni ^b   Agnantis, Niki ^a   Fountzilas, George ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

Author keywords

Bcl 2; HER 2; Ovarian cancer; p53; Prognostic factors

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247103322     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Conte PF, Cianci C and Gadducci A: Up date in the management of advanced ovarian carcinoma. Crit Rev Oncol Hematol 32: 49-58, 1999.
2. Aunoble B, Sanches R, Didier E and Bignon YJ: Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 16: 567-576, 2000.
3. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC and Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-1228, 1995.
4. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW and Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79, 1996.
5. Singleton TP, Niehans GA, Gu F, Litz CE, Hagen K, Qiu Q, Kiang DT and Strickler JG: Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23: 1141-1150, 1992.
6. Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, Rochard F, Bernaudin JF and Riou G: c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 64: 146-151, 1995.
7. Medl M, Sevelda P, Czerwenka K, Dobianer K, Hanak H, Hruza C, Klein M, Leodolter S, Mullauer-Ertl S and Rosen A: DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol 59: 321-326, 1995.
8. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R and Bermejo B: Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 75: 2147-2152, 1995.
9. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W and Schauer A: Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45-53, 1994.
10. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso, D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J and Pujade-Lauraine E: HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 15: 104-112, 2004.
11. van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG and de Vries EG: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70-78, 1995.
12. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
13. Gannon JV, Greaves R, Iggo R and Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. Embo J 9: 1595-1602, 1990.
14. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA and Roche PC: Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12: 64-69, 1994.
15. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K and Joensuu H: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201-1208, 1995.
16. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G and Diamandis EP: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327-1338, 1995.
17. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR and Blumenson LE: p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80: 892-898, 1997.
18. Skirnisdottir I, Seidal T, Gerdin E and Sorbe B: The prognostic importance of p53, Bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer 12: 265-276, 2002.
19. Sengupta PS, McGown AT, Bajaj V, Blackhall F, Swindell R, Bromley M, Shanks JH, Ward T, Buckley CH, Reynolds K, Slade RJ and Jayson GC: p53 and related proteins in epithelial ovarian cancer. Eur J Cancer 36: 2317-2328, 2000.
20. Gadducci A, Cianci C, Cosio S, Camino F, Fanucchi A, Buttitta F, Conte PF and Genazzani AR: p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res 20: 4793-4799, 2000.
21. Shahin MS, Hughes JH, Sood AK and Buller RE: The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89: 2006-2017, 2000.
22. Berker B, Dunder I, Ensari A and Cengiz SD: Prognostic value of p53 accumulation in epithelial ovarian carcinomas. Arch Gynecol Obstet 266: 205-209, 2002.
23. Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J and Berchuck A: Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21: 3814-3825, 2003.
24. Ferrandina G, Fagotti A, Salerno MG, Natali PG, Mottolese M, Maneschi F, De Pasqua A, Benedetti-Panici P, Mancuso S and Scambia G: p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 81: 733-740, 1999.
25. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR and Bevilacqua G: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235, 1997.
26. Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W and Schauer A: Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 34: 845-850, 1998.
27. Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C and Borresen-Dale AL: Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 78: 375-381, 1998.
28. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G and Zunino F: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18: 3936-3945, 2000.
29. Coultas L and Strasser A: The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 13: 115-123, 2003.
30. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M and Lohrs U: Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105: 341-349, 1996.
31. Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, Kuhn W and Schauer A: Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 17: 2233-2240, 1997.
32. Silvestrini R, Daidone MG, Veneroni S, Benini E, Scarfone G, Zanaboni F, Villa A, Presti M, Danese S and Bolis G: The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 82: 159-167, 1998.
33. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184, 1996.
34. Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, Ishii K and Nagata I: Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 35: 1214-1219, 1999.
35. Baekelandt M, Kristensen GB, Nesland JM, Trope CG and Holm R: Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol 17: 2061-2068, 1999.
36. Serov SF and Scully RE: Histological typing of ovarian tumors. In: International Histological Classification of Tumors, No 9. World Health Organization, Geneva, Switzerland, 1973.
37. Roche PC and Ingle JN: Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 17: 434-435, 1999.
38. Hogdall EV, Kjaer SK, Glud E, Christensen L, Blaakaer J, Vuust J, Bock JE, Norgaard-Pedersen B and Hogdall CK: Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. Anticancer Res 23: 3397-3404, 2003.